Takeda
Life Sciences Radar, October 2026 edition. Evidence published up to 5 October 2026; job sites read on 6 October 2026. This brief covers AI in drug discovery, and research labs and data. Every link opens the public source.
Disclosure: Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier. Software vendors, including Sapio and its competitors, appear in this brief only where public sources name them.
Status: Ortent has reviewed this brief; it has not been independently validated. It sets out what the company and others have published. Search coverage varies by company and is described under Coverage limits, and a count of zero means none was identified, not that nothing happened. It does not predict buying intent or measure operational maturity. For this radar, process and CMC development are grouped with manufacturing and excluded from research labs and data.
Scores
| Theme | Priority (1 to 10) | Delivery (0 to 10) | Stage | Commitments made public, last 12 months | R&D roles open on 6 Oct 2026 |
|---|---|---|---|---|---|
| AI in drug discovery | 4 | 2 | funded or contracted | 5 | 16 |
| Research labs and data | No eligible company disclosure identified | No eligible company disclosure identified | 2 | 9 |
The scores rest only on what the company itself has published about each theme. Commitments and open roles are observed activity: they show what is being started or staffed now, and they never change a score.
Summary
Takeda says it aims to embed AI into every stage of drug discovery, and AI in drug discovery scores 4 out of 10 for priority and 2 for delivery, at the funded or contracted stage. Delivery rests on signed partnerships; the sources show no identifiable system in operation. Five AI in drug discovery commitments were made public in the last 12 months: collaborations with Nabla Bio, Iambic, Boltz and Insilico Medicine, and the Labs of Tomorrow programme with its AIRx and discovery automation and robotics (DAR) units; one was made public in the year before. For research labs and data, no eligible company disclosure was identified, although Labs of Tomorrow and Takeda's founding partner role in the TetraScience Scientific AI Lighthouse (SAIL) programme were made public in the last 12 months. On 6 October 2026 Takeda had 16 R&D roles open in AI in drug discovery and 9 in research labs and data, many tied to Labs of Tomorrow, and two postings name TetraScience and SAIL as AIRx data systems.
AI in drug discovery
What the company says: Priority 4
We seek to achieve a foundational shift that embeds AI into every stage of drug discovery, redesigning workflows to include automated, data-driven, predictive processes that accelerate innovation.
Takeda Annual Report on Form 20-F for FY2025 (year ended 31 March 2026), 17 Jun 2026, p. 25
By using advanced models to predict how molecules will behave, we can identify high-quality candidates earlier and rapidly optimize their design.
Takeda 2026 Annual Integrated Report (FY2025), 27 Jun 2026, p. 8
Through bold investments in digital, data and AI-driven capabilities, our teams are delivering for patients at speed and scale.
Takeda 2026 Annual Integrated Report (FY2025), 27 Jun 2026, p. 8
What it shows running: Delivery 2, funded or contracted
Iambic Therapeutics U.S. Cross-therapeutic area discovery research alliance to leverage Iambic’s computational-driven discovery engine
Takeda Annual Report on Form 20-F for FY2025 (year ended 31 March 2026), 17 Jun 2026, p. 49
By using advanced models to predict how molecules will behave, we can identify high-quality candidates earlier and rapidly optimize their design.
Takeda 2026 Annual Integrated Report (FY2025), 27 Jun 2026, p. 8
Commitments made public in the last 12 months: 5
- Insilico Medicine Pharma.AI collaboration: Announced a strategic collaboration agreement under which Insilico will use its Pharma.AI platform to advance drug candidates across Takeda therapeutic areas. New, announced, 1 Jul 2026. Published by: partner release, company quoted.
- Labs of Tomorrow (AIRx, DAR, automated discovery labs): Takeda job posting states Takeda is building a Lab of Tomorrow intended to create a fully automated, closed-loop, AI-integrated drug discovery platform. New, in build, 27 Jun 2026. Published by: company.
- Boltz biomolecular foundation model platform deployment: Announced a collaboration to provide Boltz models and platform access across Takeda Research. New, announced, 18 Jun 2026. Published by: partner release, company quoted.
- Iambic AI small-molecule collaboration: Multi-year AI small-molecule discovery collaboration that will use Iambic's AI models, with technology access payments. New, announced, 9 Feb 2026. Published by: partner release, company quoted.
- Nabla Bio second AI protein design collaboration (JAM platform): Announced a second multi-year Nabla Bio collaboration under which Nabla's JAM design platform will be deployed across Takeda early-stage programmes. New, announced, 14 Oct 2025. Published by: partner release, company quoted.
Commitments made public in the year before: 1
- AISB Network Federated OpenFold3 (Apheris): Takeda joins AISB Network Federated OpenFold3 initiative, contributing proprietary structures. New, announced, 1 Oct 2025. Published by: partner release, company quoted.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 16
- Head of Biologics Engineering & Next-Generation Platform Innovation, Boston, Massachusetts, United States
- Associate Director, AI/ML (Biologics), Boston, Massachusetts, United States
- Lead Product Owner, Labs of Tomorrow Small Molecule, Boston, Massachusetts, United States
- Technical Product Owner, AI-native Large molecule Discovery, Boston, Massachusetts, United States
- Associate Director or Senior Scientist, Computational Chemistry, Research, Fujisawa, Kanagawa, Japan
- Senior Director, AIRx DMPK & Modeling Lead, Boston, Massachusetts, United States
- Business Lead, AI-native Target Identification & Validation (TIDVAL), Boston, Massachusetts, United States
- Business Lead, AI-native Large Molecule / Biologics Discovery, Boston, Massachusetts, United States
- Business Lead, AI-native Small Molecule Discovery, Boston, Massachusetts, United States
- Research Scientist, Molecular AI, Boston, Massachusetts, United States
- Research Senior Scientist, Cheminformatics AI/ML, Boston, Massachusetts, United States
- Research Strategy Development & Integration Lead, Boston, Massachusetts, United States
- Director, AIRx External Partnership Management Lead, Boston, Massachusetts, United States
- Lead, Search & Evaluation, AI and Automation Drug Discovery, Cambridge, Massachusetts, United States
- AIRx, Sr. Director, Nonclinical Safety Lead, Boston, Massachusetts, United States
- Senior Director, AIRx Discovery Biology Lead, Boston, Massachusetts, United States
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Technology named in these postings
Named as in use: SAIL (TetraScience programme), TetraScience.
Asked for as experience: Python.
A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.
Research labs and data
No eligible company disclosure identified for this theme in the reviewed sources and period. This is not a finding that the company is inactive.
Commitments made public in the last 12 months: 2
- Labs of Tomorrow (AIRx, DAR, automated discovery labs): Takeda job posting states Takeda is building a Lab of Tomorrow intended to create a fully automated, closed-loop, AI-integrated drug discovery platform. New, in build, 27 Jun 2026. Published by: company.
- TetraScience Scientific AI Lighthouse (SAIL): Takeda founding partner of TetraScience Scientific AI Lighthouse programme for scientific data. New, announced, 23 Oct 2025. Published by: partner release, company quoted.
Commitments made public in the year before: 0
None identified in the reviewed sources.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 9
- Lead Technical Product Owner, AI-native End Point Generation, Boston, Massachusetts, United States
- Technical Product Owner, Discovery, Automation and Robotics (DAR), Boston, Massachusetts, United States
- Director, Automation Lead (Labs of Tomorrow) - Takeda Shonan (TSHO), Fujisawa-shi, Kanagawa, Japan
- Business Lead, AI-native Discovery Automation & Robotics, Boston, Massachusetts, United States
- Business Lead, AI-native End Point Generation, Boston, Massachusetts, United States
- Manager, AI-Ready Data Modeling, Boston, Massachusetts, United States
- Research Strategy Development & Integration Lead, Boston, Massachusetts, United States
- Lead, Search & Evaluation, AI and Automation Drug Discovery, Cambridge, Massachusetts, United States
- Global Head - Small Molecule In Vitro Pharmacology (Automation), Boston, Massachusetts, United States
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Two questions to investigate (Ortent's interpretation)
- Two postings name TetraScience and SAIL as AIRx data systems, while several new roles must integrate with existing ELN and LIMS systems that no posting names. What is the remit of the AIRx data systems against those existing systems, and who decides on additions?
- Takeda is hiring an AIRx external partnership lead and a search and evaluation lead for AI and automation in discovery. What decision rights do these roles hold over external tools, and is Labs of Tomorrow funding committed through the R&D President's retirement in June 2027 and the company-wide savings programme?
Coverage limits
Takeda's venture site, takedaventures.com, could not be reached, so corporate venture activity was searched by web search only. Business Wire blocked access, so the Nabla Bio release was read through copies, and the internet archive was unavailable, so the start dates of Labs of Tomorrow, AIRx and DAR could not be traced. Careers search pages block automated access, so roles were found through the sitemap and individual job pages. Patents were not counted, and venture and publication sources were not covered equally in both years, so the two years are not a full like-for-like comparison.
Clarity when it counts.
For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.
Request a 30-minute intro call